The biggest constraint on the weight-loss drug boom may not be science or demand — it's finding enough people who know how to make the drugs. As GLP-1 receptor agonists surge from niche diabetes treatments to global blockbusters, the industry faces a growing shortage of specialized manufacturing talent.
Why these drugs are hard to make
GLP-1 production is unusually complex, spanning several routes: peptide-based chemical synthesis, recombinant technologies using yeast or mammalian cells, and newer oral formulations. Each demands a different, hard-to-hire skill set across synthetic chemistry, protein expression, quality, and regulatory work — and the workforce hasn't scaled as fast as the market.
“These medicines have evolved quickly from niche drugs to treat diabetes when first launched to, now, blockbuster status,” said John Milne, PhD, director of Ireland's NIBRT, per GEN.
The build-out
The capacity race is visible in bricks and mortar. Novo Nordisk announced a €400 million-plus expansion at its Athlone facility in Ireland for oral Wegovy, while Eli Lilly's Kinsale campus anchors another manufacturing hub. Training programs are springing up to close the skills gap.
Why it matters
For patients, this is the unglamorous reason GLP-1 supply has repeatedly lagged demand. For the industry, manufacturing capability — not just pipeline — is becoming a competitive advantage. Whoever can build and staff capacity fastest gets to convert demand into sales.